Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia

In sickle cell disease (SCD), hydroxyurea (HU) treatment decreases the number of vaso-occlusive crisis (VOC) and acute chest syndrome (ACS) by increasing fetal hemoglobin (HbF). Data are lacking regarding the frequency of HU dose modification or whether sub-therapeutic doses (<15 mg/kg/day) are b...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Maggio, Rosario, Hsieh, Matthew M., Zhao, Xiongce, Calvaruso, Giuseppina, Rigano, Paolo, Renda, Disma, Tisdale, John F., Maggio, Aurelio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877542/
https://www.ncbi.nlm.nih.gov/pubmed/29495591
http://dx.doi.org/10.3390/ijms19030681

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877542/
https://www.ncbi.nlm.nih.gov/pubmed/29495591
http://dx.doi.org/10.3390/ijms19030681

Ejemplares similares